Investing in Nkarta entails significant risks primarily inherent to early-stage, clinical-phase biotechnology companies operating without commercial product revenue. The corporation's financial stability and equity value depend almost entirely on successful clinical trial outcomes for its engineered natural killer cell therapies targeting cancer and autoimmune diseases. Adverse trial data, regulatory delays, unexpected safety profiles, and the continuous need for capital dilution through secondary stock offerings represent major financial hazards that can cause steep share price declines.